Events

Event When
Half-Year 2018 Financial Results reporting 24 July 2018
9 Months 2018 Financial Results reporting 23 October 2018
Full-Year 2018 Financial Results reporting 7 February 2019

Phase 3 initiation: Lucerastat for Fabry disease

In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.

 

Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

Date:  Wednesday May 16, 2018

Time:  14:00 CEST | 13:00 BST | 08:00 EDT

CH: +41 44 580 65 22  |  UK: +44 203 009 24 70  |  US: +1 877 423 08 30

PIN: 32979293#

Phase 3 initiation: Lucerastat for Fabry disease

Full Year 2017 Financial Results

Idorsia published its full year financial results 2017 on Tuesday 6 February 2018.

 Full Year 2017 Financial Results

Stay Informed

Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.

Stay Informed

Contact

Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland